19 Apr 2016 07:00
The announcement text is unchanged and is reproduced in full below.
Silence Therapeutics plc
("Silence" or "the Company")
Director's dealings
Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, announces that on 18 April 2016 it received notification that, on the same day, the following purchases of ordinary shares in the Company ("Ordinary Shares") were made:
Ali Mortazavi, Chief Executive of the Company, purchased 160,000 Ordinary Shares at a price of 125.00 pence per Ordinary Share.
Stephen Parker, Chairman of the Company, purchased 6,478 Ordinary Shares at a price of 123.31p per Ordinary Share.
Following the above purchases, Ali Mortazavi holds a beneficial interest in 1,937,399 Ordinary Shares, representing 2.78% of the Company's issued share capital. Stephen Parker holds 6,478 Ordinary Shares, representing 0.01% of the Company's issued share capital.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer | Tel: +44 (0)20 3457 6900
|
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel/Ben Griffiths | Tel: +44 (0)20 7523 8350
|
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert | Tel: +44 (0) 20 3727 1000
|
Notes to Editors
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics.